FORA Capital LLC Invests $6.07 Million in DexCom, Inc. (NASDAQ:DXCM)

FORA Capital LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to its most recent filing with the SEC. The fund purchased 90,577 shares of the medical device company’s stock, valued at approximately $6,072,000.

Several other institutional investors and hedge funds have also made changes to their positions in DXCM. Kennedy Capital Management LLC acquired a new stake in shares of DexCom during the first quarter worth $1,690,000. B. Riley Wealth Advisors Inc. raised its stake in DexCom by 132.0% during the first quarter. B. Riley Wealth Advisors Inc. now owns 3,766 shares of the medical device company’s stock worth $522,000 after acquiring an additional 2,143 shares during the period. Tidal Investments LLC raised its stake in DexCom by 151.8% during the first quarter. Tidal Investments LLC now owns 37,439 shares of the medical device company’s stock worth $5,193,000 after acquiring an additional 22,572 shares during the period. iA Global Asset Management Inc. lifted its holdings in DexCom by 2.1% in the first quarter. iA Global Asset Management Inc. now owns 81,003 shares of the medical device company’s stock worth $11,235,000 after acquiring an additional 1,694 shares during the last quarter. Finally, Plato Investment Management Ltd boosted its stake in DexCom by 469.4% in the first quarter. Plato Investment Management Ltd now owns 13,763 shares of the medical device company’s stock valued at $1,909,000 after acquiring an additional 11,346 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,431 shares of company stock worth $399,319. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of research reports. Oppenheimer dropped their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Piper Sandler reiterated an “overweight” rating and issued a $90.00 target price on shares of DexCom in a research note on Monday, August 26th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Wells Fargo & Company increased their price objective on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Finally, Royal Bank of Canada reduced their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Price Performance

DXCM stock traded down $0.63 during trading hours on Wednesday, hitting $77.31. 200,444 shares of the stock traded hands, compared to its average volume of 3,923,553. The stock has a 50-day simple moving average of $70.94 and a 200 day simple moving average of $88.58. The company has a market cap of $30.20 billion, a P/E ratio of 46.67, a P/E/G ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.